Submissions from 2020
Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research., Désirée van der Heijde, Dafna D Gladman, Arthur Kavanaugh, and Philip Mease
Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5., Désirée van der Heijde, Philip Mease, Robert B M Landewé, Proton Rahman, Hasan Tahir, Atul Singhal, Elke Boettcher, Sandra Navarra, Xuan Zhu, Gregory Ligozio, Aimee Readie, Shephard Mpofu, and Luminita Pricop
Proceedings of the 2019 GRAPPA Collaborative Research Network Meeting., Robin Waxman, Carmel Stober, Deepak R Jadon, Ana-Maria Orbai, Vinod Chandran, Alexis Ogdie, Stephen R Pennington, Maarten de Wit, Denis O'Sullivan, Philip Mease, April W Armstrong, Kristina Callis Duffin, Philip S Helliwell, Leonieke J J van Mens, Christopher T Ritchlin, and Oliver FitzGerald
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019., Kevin L Winthrop, Michael E Weinblatt, Joan Bathon, Gerd R Burmester, Philip Mease, Leslie Crofford, Vivian Bykerk, Maxime Dougados, James Todd Rosenbaum, Xavier Mariette, Joachim Sieper, Fritz Melchers, Bruce N Cronstein, Ferry C Breedveld, Joachim Kalden, Josef S Smolen, and Daniel Furst
Submissions from 2019
Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial population., Diana Brixner, Manish Mittal, David T Rubin, Philip Mease, Harry H Liu, Matthew Davis, Arijit Ganguli, and A Mark Fendrick
Pain Measurement in Rheumatic and Musculoskeletal Diseases: Where To Go from Here? Report from a Special Interest Group at OMERACT 2018., Alessandro Chiarotto, Ulrike Kaiser, Ernest Choy, Robin Christensen, Philip G Conaghan, Mary Cowern, Michael Gill, Maarten de Wit, Elizabeth Gargon, Ben Horgan, Jamie J Kirkham, Lee S Simon, Jasvinder A Singh, Peter Tugwell, Dennis C Turk, and Philip Mease
Pain Measurement in Rheumatic and Musculoskeletal Diseases: Where To Go from Here? Report from a Special Interest Group at OMERACT 2018., Alessandro Chiarotto, Ulrike Kaiser, Ernest Choy, Robin Christensen, Philip G Conaghan, Mary Cowern, Michael Gill, Maarten de Wit, Elizabeth Gargon, Ben Horgan, Jamie J Kirkham, Lee S Simon, Jasvinder A Singh, Peter Tugwell, Dennis C Turk, and Philip Mease
Measurement properties of the minimal disease activity criteria for psoriatic arthritis., Laura C Coates, Vibeke Strand, Hilary Wilson, Dennis Revicki, Brad Stolshek, Ahmed Samad, James B Chung, Dafna Gladman, and Philip Mease
Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies., Laura C Coates, Johan K Wallman, Dennis McGonagle, Georg A Schett, Iain B McInnes, Philip Mease, Lawrence Rasouliyan, Erhard Quebe-Fehling, Darren L Asquith, Andreas E R Fasth, Luminita Pricop, and Corine Gaillez
Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies., Laura C Coates, Johan K Wallman, Dennis McGonagle, Georg A Schett, Iain B McInnes, Philip Mease, Lawrence Rasouliyan, Erhard Quebe-Fehling, Darren L Asquith, Andreas E R Fasth, Luminita Pricop, and Corine Gaillez
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data., A Deodhar, Philip Mease, I B McInnes, X Baraliakos, K Reich, A Blauvelt, C Leonardi, B Porter, A Das Gupta, A Widmer, L Pricop, and T Fox
Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap., Atul Deodhar, Lianne S Gensler, Marina Magrey, Jessica A Walsh, Adam Winseck, Daniel Grant, and Philip Mease
Endorsement of the 66/68 joint count for the measurement of musculoskeletal disease activity: OMERACT 2018 Psoriatic Arthritis workshop report., Alí Duarte-García, Ying Ying Leung, Laura C Coates, Dorcas Beaton, Robin Christensen, Ethan T Craig, Maarten de Wit, Lihi Eder, Lara Fallon, Oliver FitzGerald, Dafna D Gladman, Niti Goel, Richard Holland, Chris Lindsay, Lara Maxwell, Philip Mease, Ana Maria Orbai, Bev Shea, Vibeke Strand, Douglas J Veale, William Tillett, and Alexis Ogdie
GRAPPA 2018 Project Report., Niti Goel, Oliver FitzGerald, Dafna D Gladman, Philip S Helliwell, Arthur Kavanaugh, Walter P Maksymowych, Philip Mease, Christopher T Ritchlin, and Laura C Coates
Pain Mechanisms and Ultrasonic Inflammatory Activity as Prognostic Factors in Patients With Psoriatic Arthritis: A Prospective Cohort Study., Pil Højgaard, Karen Ellegaard, Sabrina Mai Nielsen, Robin Christensen, Jørgen Guldberg-Møller, Christine Ballegaard, Lene Dreyer, Philip Mease, Maarten de Wit, Lone Skov, Bente Glintborg, Henning Bliddal, Else Marie Bartels, Kirstine Amris, and Lars Erik Kristensen
Prevalence of Crystals in Knee Osteoarthritis: Experience From Patients Undergoing Arthroscopic Procedures., Robert Ike, Amrutha Baskaran, Jeannie Chao, Andrew L Concoff, Christopher W Wu, Bob Sun, Paul H Brion, Erin L Arnold, David J Klashman, John FitzGerald, and Kenneth C Kalunian
Proceedings of the 2018 GRAPPA Collaborative Research Network Meeting., Deepak R Jadon, Vinod Chandran, Alexis Ogdie, Stephen R Pennington, Carmel Stober, Dafna D Gladman, Maarten de Wit, Denis O'Sullivan, Philip Mease, April W Armstrong, Kristina Callis Duffin, Conor Magee, Philip Helliwell, Christopher T Ritchlin, and Oliver FitzGerald
Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis., Arthur Kavanaugh, Dafna D Gladman, Christopher J Edwards, Georg Schett, Benoit Guerette, Nikolay Delev, Lichen Teng, Maria Paris, and Philip Mease
The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set., Ying Ying Leung, Ana-Maria Orbai, Alexis Ogdie, Laura C Coates, Maarten de Wit, Kristina Callis Duffin, Lihi Eder, Dafna D Gladman, Niti Goel, Philip Mease, Vibeke Strand, Oliver FitzGerald, and William Tillett
Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a, Iain B McInnes, Gianfranco Ferraccioli, Maria-Antonietta D'Agostino, Manuela Le Bars, Subhashis Banerjee, Harris A Ahmad, Yedid Elbez, and Philip Mease
Emerging Immunomodulatory Therapies and New Treatment Paradigms for Axial Spondyloarthritis., Philip Mease
Ustekinumab Fails to Show Efficacy in a Phase III Axial Spondyloarthritis Program: The Importance of Negative Results., Philip Mease
Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting., Philip Mease, Neil A Accortt, Sabrina Rebello, Carol J Etzel, Ryan W Harrison, Girish A Aras, Mahdi M F Gharaibeh, Jeffrey D Greenberg, and David H Collier
Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry., Philip Mease, Carol J Etzel, William J Huster, Talia M Muram, April W Armstrong, Jeffrey R Lisse, Sabrina Rebello, Rhiannon Dodge, Mwangi James Murage, Jeffrey D Greenberg, and William N Malatestinic
Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase 3 Trial., Philip Mease, Dafna D Gladman, David H Collier, Christopher T Ritchlin, Philip S Helliwell, Lyrica Liu, Gregory Kricorian, and James B Chung
Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry., Philip Mease, Chitra Karki, Mei Liu, YouFu Li, Bernice Gershenson, Hua Feng, Peter Hur, and Jeffrey D Greenberg
Axial Spondyloarthritis, Philip Mease and Muhammad Asim Khan
Impact of Clinical Specialty Setting and Geographic Regions on Disease Management in Patients with Psoriatic Arthritis in the United States: A Multicenter Observational Study., Philip Mease, Clive Liu, Evan Siegel, Heather Richmond, Meijing Wu, Liang Chen, Kevin Douglas, and Benjamin Lockshin
Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from Two Corrona Registries., Philip Mease, Mei Liu, Sabrina Rebello, Hyungjoo Kang, Esther Yi, Yujin Park, and Jeffrey D Greenberg
Utilization of the validated Psoriasis Epidemiology Screening Tool (PEST) to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry., Philip Mease, J B Palmer, P Hur, B E Strober, M Lebwohl, C Karki, G W Reed, C J Etzel, J D Greenberg, and P S Helliwell
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial., Philip Mease, Josef S Smolen, Frank Behrens, Peter Nash, Soyi Liu Leage, Lingnan Li, Hasan Tahir, Melinda Gooderham, Eswar Krishnan, Hong Liu-Seifert, Paul Emery, Sreekumar G Pillai, and Philip S Helliwell
Biologic Treatment of Axial Spondyloarthritis, Philip Mease and F. Van den Bosch
Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis., Philip Mease, Jessica A Walsh, Xenofon Baraliakos, Robert Inman, Kurt de Vlam, James Cheng-Chung Wei, Theresa Hunter, Gaia Gallo, David Sandoval, Fangyi Zhao, Yan Dong, Rebecca Bolce, and Helena Marzo-Ortega
The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis., Philippe Mertz, Alexandre Belot, Ricard Cervera, Tyng Yu Chuah, Lorenzo Dagna, Laura Damian, Debashish Danda, David D'cruz, Gerard Espinosa, Camille Frances, David Jayne, Kong Kok Ooi, Eugene J Kucharz, Robert Lebovics, Isabelle Marie, Guillaume Moulis, Stanford Peng, Aman Sharma, Noboru Suzuki, Toshio Tanaka, Ronald Van Vollenhoven, Jean Sibilia, Jacques Eric Gottenberg, François Chasset, and Laurent Arnaud
Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor., Alexis Ogdie, J Lynn Palmer, Jeffrey Greenberg, Jeffrey R Curtis, Leslie R Harrold, Daniel H Solomon, Arthur Kavanaugh, Joel M Kremer, and Philip Mease
Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients., Ana-Maria Orbai, Iain B McInnes, Laura C Coates, M Elaine Husni, Dafna D Gladman, Laure Gossec, Luminita Pricop, Olivier Chambenoit, Xiangyi Meng, and Philip Mease
Measuring Psoriatic Arthritis Symptoms, A Core Domain in Psoriasis Clinical Trials., Lourdes Maria Perez-Chada, Alice Bendix Gottlieb, Jeffrey Cohen, Philip Mease, Kristina Callis Duffin, Amit Garg, John Latella, April Wang Armstrong, Alexis Ogdie, and Joseph Frank Merola
Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial., Thomas J Schnitzer, Richard Easton, Shirley Pang, Dennis J Levinson, Glenn Pixton, Lars Viktrup, Isabelle Davignon, Mark T Brown, Christine R West, and Kenneth M Verburg
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis., Jasvinder A Singh, Gordon Guyatt, Alexis Ogdie, Dafna D Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan Dunham, M Elaine Husni, Sarah Kenny, Jennifer Kwan-Morley, Janice Lin, Paula Marchetta, Philip Mease, Joseph F Merola, Julie Miner, Christopher T Ritchlin, Bernadette Siaton, Benjamin J Smith, Abby S Van Voorhees, Anna Helena Jonsson, Amit Aakash Shah, Nancy Sullivan, Marat Turgunbaev, Laura C Coates, Alice Gottlieb, Marina Magrey, W Benjamin Nowell, Ana-Maria Orbai, Soumya M Reddy, Jose U Scher, Evan Siegel, Michael Siegel, Jessica A Walsh, Amy S Turner, and James Reston
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis., Jasvinder A Singh, Gordon Guyatt, Alexis Ogdie, Dafna D Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan Dunham, M Elaine Husni, Sarah Kenny, Jennifer Kwan-Morley, Janice Lin, Paula Marchetta, Philip Mease, Joseph F Merola, Julie Miner, Christopher T Ritchlin, Bernadette Siaton, Benjamin J Smith, Abby S Van Voorhees, Anna Helena Jonsson, Amit Aakash Shah, Nancy Sullivan, Marat Turgunbaev, Laura C Coates, Alice Gottlieb, Marina Magrey, W Benjamin Nowell, Ana-Maria Orbai, Soumya M Reddy, Jose U Scher, Evan Siegel, Michael Siegel, Jessica A Walsh, Amy S Turner, and James Reston
Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study., Josef S Smolen, Dafna Gladman, H Patrick McNeil, Philip J Mease, Joachim Sieper, Maja Hojnik, Pascal Nurwakagari, and John Weinman
Consumer Prices for Surgical Management of Ankle Arthritis: Limited Availability and Wide Variability., Niall A Smyth, Brody J Dawkins, Joshua P Goldstein, Jonathan R Kaplan, Lew C Schon, and Amiethab A Aiyer
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond., Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, Philip Mease, Dafna D Gladman, Linda Chen, Elizabeth Kudlacz, Joseph Wu, Joseph C Cappelleri, Thijs Hendrikx, and Ming-Ann Hsu
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs., Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, Philip Mease, Dafna D Gladman, Daniela Graham, Cunshan Wang, Joseph C Cappelleri, Thijs Hendrikx, and Ming-Ann Hsu
Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis., Vibeke Strand, Iain McInnes, Philip Mease, Peter Nash, Howard Thom, Chrysostomos Kalyvas, Matthias Hunger, Kunal Gandhi, Luminita Pricop, Steffen Jugl, and Ernest Choy
Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5., Désirée van der Heijde, Philip Mease, Robert B M Landewé, Proton Rahman, Hasan Tahir, Atul Singhal, Elke Boettcher, Sandra Navarra, Xuan Zhu, Gregory Ligozio, Aimee Readie, Shephard Mpofu, and Luminita Pricop
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019., Kevin L Winthrop, Michael E Weinblatt, Joan Bathon, Gerd R Burmester, Philip Mease, Leslie Crofford, Vivian Bykerk, Maxime Dougados, James Todd Rosenbaum, Xavier Mariette, Joachim Sieper, Fritz Melchers, Bruce N Cronstein, Ferry C Breedveld, Joachim Kalden, Josef S Smolen, and Daniel Furst
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018., Kevin L Winthrop, Michael E Weinblatt, Mary K Crow, Gerd R Burmester, Philip Mease, Alexander K So, Vivian Bykerk, Ronald F Van Vollenhoven, Maxime Dougados, Jonathan Kay, Xavier Mariette, Joachim Sieper, Fritz Melchers, Bruce N Cronstein, Ethan Shevach, Ferdinand C Breedfeld, Joachim Kalden, Josef S Smolen, and Daniel E Furst
Revised chronic widespread pain criteria: development from and integration with fibromyalgia criteria., Frederick Wolfe, Stephen H Butler, MaryAnn Fitzcharles, Winfried Häuser, Robert L Katz, Philip Mease, Johannes J Rasker, Anthony S Russell, I Jon Russell, and Brian Walitt
Revised chronic widespread pain criteria: development from and integration with fibromyalgia criteria., Frederick Wolfe, Stephen H Butler, MaryAnn Fitzcharles, Winfried Häuser, Robert L Katz, Philip Mease, Johannes J Rasker, Anthony S Russell, I Jon Russell, and Brian Walitt
Submissions from 2018
Anti-Inflammatory Effects of Intra-Articular Hyaluronic Acid: A Systematic Review., Roy Altman, Asheesh Bedi, Ajay Manjoo, Faizan Niazi, Peter Shaw, and Philip Mease
Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic Study., Christine Ballegaard, Tanja S Jørgensen, Marie Skougaard, Vibeke Strand, Philip Mease, Lars E Kristensen, Lene Dreyer, Alice Gottlieb, Maarten de Wit, Robin Christensen, and Simon Tarp
Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study., Matthew A Brown, Paul A Bird, Philip C Robinson, Philip Mease, Filip van den Bosch, Christine Surian, Heather Jones, Annette Szumski, Lisa Marshall, Zirke Wiid, and Maxime Dougados
GRAPPA 2017 Project Report., Kristina Callis Duffin, Oliver FitzGerald, Artie Kavanaugh, Philip Mease, Joseph F Merola, Alexis Ogdie, Denis O'Sullivan, Soumya M Reddy, Christopher T Ritchlin, and Laura C Coates
Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study., Alberto Cauli, Dafna D Gladman, Alessandro Mathieu, Ignazio Olivieri, Giovanni Porru, Paul P Tak, Claudia Sardu, Raffaele Scarpa, Antonio Marchesoni, William J Taylor, Carlo Salvarani, Joachim Kalden, Ennio Lubrano, Sueli Carneiro, Matteo Piga, Alberto Floris, Francesca Desiati, John A Flynn, Salvatore D'Angelo, Arno W R van Kuijk, Maria Grazia Catanoso, Francesco Caso, Paolo Contu, Ilona Ujfalussy, Philip S Helliwell, and Philip Mease
Remission in psoriatic arthritis-where are we now?, Laura C Coates, Philip G Conaghan, Maria Antonietta D'Agostino, Maarten De Wit, Oliver FitzGerald, Tore K Kvien, Rik Lories, Philip Mease, Peter Nash, Georg Schett, Enrique R Soriano, and Paul Emery
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis., Laura C Coates, Oliver FitzGerald, Joseph F Merola, Josef Smolen, Leonieke J J van Mens, Heidi Bertheussen, Wolf-Henning Boehncke, Kristina Callis Duffin, Willemina Campbell, Maarten de Wit, Dafna Gladman, Alice Gottlieb, Jana James, Arthur Kavanaugh, Lars Erik Kristensen, Tore K Kvien, Thomas Luger, Neil McHugh, Philip Mease, Peter Nash, Alexis Ogdie, Cheryl F Rosen, Vibeke Strand, William Tillett, Douglas J Veale, and Philip S Helliwell
Minimal Disease Activity among Active Psoriatic Arthritis Patients Treated with Secukinumab: 2-year Results from the FUTURE 2 Study., Laura C Coates, Philip Mease, Laure Gossec, Bruce Kirkham, Bintu Sherif, Corine Gaillez, Shephard Mpofu, Steffen M Jugl, Chetan Karyekar, and Kunal K Gandhi
Opioids vs Nonopioids for Chronic Back, Hip, or Knee Pain., Edward Covington, Charles Argoff, and Steven P Stanos
Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis., Mark C Genovese, Michael E Weinblatt, Philip J Mease, Jacob A Aelion, Paul M Peloso, Kun Chen, Yihan Li, John Liu, Ahmed A Othman, Amit Khatri, Heikki T Mansikka, and Piotr Leszczynski
The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database., Dafna D Gladman, Laura C Coates, Deepak R Jadon, William Tillett, Philip Mease, and Marijn Vis
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies., Dafna D Gladman, Arthur Kavanaugh, Juan J Gómez-Reino, Jürgen Wollenhaupt, Maurizio Cutolo, Georg Schett, Eric Lespessailles, Benoit Guerette, Nikolay Delev, Lichen Teng, Christopher J Edwards, Charles A Birbara, and Philip J Mease
The Effect of Psoriatic Arthritis on Ixekizumab Clinical Outcomes in Moderate-to-Severe Psoriasis Patients: A Post Hoc Analysis., Alice B Gottlieb, Kim A Papp, Charles A Birbara, Catherine L Shuler, Russel Burge, Janelle Erickson, Lisa Kerr, and Philip J Mease
Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)., Alice B Gottlieb, Vibeke Strand, Mitsumasa Kishimoto, Philip Mease, Diamant Thaçi, Julie Birt, Chin H Lee, Catherine L Shuler, Chen-Yen Lin, and Dafna D Gladman
Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: A prospective cohort study., Pil Højgaard, Karen Ellegaard, Sabrina Mai Nielsen, Robin Christensen, Jørgen Guldberg-Møller, Christine Ballegaard, Lene Dreyer, Philip Mease, Maarten de Wit, Lone Skov, Bente Glintborg, Henning Bliddal, Else Marie Bartels, Kirstine Amris, and Lars Erik Kristensen
A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative., Pil Højgaard, Louise Klokker, Ana-Maria Orbai, Kim Holmsted, Else M Bartels, Ying Ying Leung, Niti Goel, Maarten de Wit, Dafna D Gladman, Philip Mease, Lene Dreyer, Lars E Kristensen, Oliver FitzGerald, William Tillett, Laure Gossec, Philip Helliwell, Vibeke Strand, Alexis Ogdie, Caroline B Terwee, and Robin Christensen
Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting., Richard Holland, William Tillett, Alexis Ogdie, Ying Y Leung, Dafna D Gladman, Kristina Callis Duffin, Laura C Coates, Philip Mease, Lihi Eder, Vibeke Strand, Musaab Elmamoun, Pil Højgaard, Jeffrey Chau, Maarten de Wit, Niti Goel, Chris A Lindsay, Oliver FitzGerald, Bev Shea, Dorcas Beaton, and Ana-Maria Orbai
Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study., Robert Landewé, Joachim Sieper, Philip Mease, Robert D Inman, Robert G Lambert, Atul Deodhar, Helena Marzo-Ortega, Marina Magrey, Uta Kiltz, Xin Wang, Mei Li, Sheng Zhong, Nael M Mostafa, Apinya Lertratanakul, Aileen L Pangan, and Jaclyn K Anderson
Classification and Outcome Measures for Psoriatic Arthritis., Ying Ying Leung, Alexis Ogdie, Ana-Maria Orbai, William Tillett, Laura C Coates, Vibeke Strand, Philip Mease, and Dafna D Gladman
Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study., Iain B McInnes, Philip Mease, Georg Schett, Bruce Kirkham, Vibeke Strand, Nicole Williams, Todd Fox, Luminita Pricop, Steffen M Jugl, and Kunal K Gandhi
Current and Emerging Treatments for Psoriatic Arthritis, Philip Mease
Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison., Philip Mease, Ernest Choy, Peter Nash, Chrysostomos Kalyvas, Matthias Hunger, Luminita Pricop, Kunal K Gandhi, Steffen M Jugl, and Howard Thom
Considerations for the definition of remission criteria in psoriatic arthritis., Philip Mease and Laura C Coates
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial., Philip Mease, Laura C Coates, Philip S Helliwell, Mykola Stanislavchuk, Anna Rychlewska-Hanczewska, Anna Dudek, Walid Abi-Saab, Chantal Tasset, Luc Meuleners, Pille Harrison, Robin Besuyen, Annegret Van der Aa, Neelufar Mozaffarian, Joy M Greer, Rebecca Kunder, Filip Van den Bosch, and Dafna D Gladman
Phase 2 Study of ABT-122, a TNF- and IL-17A-Targeted Dual Variable Domain Immunoglobulin, in Psoriatic Arthritis With Inadequate Methotrexate Response., Philip Mease, Mark C Genovese, Michael E Weinblatt, Paul M Peloso, Kun Chen, Ahmed A Othman, Yihan Li, Heikki T Mansikka, Amit Khatri, Neil Wishart, and John Liu
Tofacitinib for Psoriatic Arthritis., Philip Mease and Dafna Gladman
Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)., Philip Mease, Dafna D Gladman, Ahmed S Samad, Laura C Coates, Lyrica X H Liu, Girish A Aras, David H Collier, and James B Chung
CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study., Philip J Mease, Slawomir Jeka, Juan Jose Jaller, Tasanee Kitumnuaypong, Worawit Louthrenoo, Herman Mann, Galina Matsievskaia, Enrique R Soriano, Bin Jia, Caihong Wang, Jing Nie, and Elizabeth Hsia
Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial., Philip J Mease, Arthur Kavanaugh, Andreas Reimold, Hasan Tahir, Jürgen Rech, Stephen Hall, Piet Geusens, Pascale Pellet, Evie Maria Delicha, Shephard Mpofu, and Luminita Pricop
Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry., Philip J Mease, Jacqueline B Palmer, Mei Liu, Arthur Kavanaugh, Renganayaki Pandurengan, Christopher T Ritchlin, Chitra Karki, and Jeffrey D Greenberg
Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry., Philip J Mease, Désirée van der Heijde, Chitra Karki, Mei Liu, Yujin Park, and Jeffrey D Greenberg
Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry., Philip Mease, Chitra Karki, Mei Liu, Arthur Kavanaugh, Christopher T Ritchlin, Doquyen Hoa Huynh, Jacqueline B Palmer, and Jeffrey D Greenberg
Correction: Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial., Philip Mease, A Kavanaugh, and A Reimold
Axial Spondyloarthritis, Philip Mease and Muhammad Asim Khan
Safety of Ixekizumab in Patients with Psoriatic Arthritis: Results from a Pooled Analysis of Three Clinical Trials., Philip Mease, Euthalia Roussou, Gerd-Rüdiger Burmester, Philippe Goupille, Alice Gottlieb, Susan R Moriarty, Olivier Benichou, David H Adams, Wen Xu, and Peter Nash
Functional impairment measurement in psoriatic arthritis: Importance and challenges., Philip Mease, Vibeke Strand, and Dafna Gladman
Characterization of Patients With Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis in the US-Based Corrona Registry., Philip Mease, Désirée van der Heijde, Chitra Karki, Jacqueline B Palmer, Mei Liu, Renganayaki Pandurengan, Yujin Park, and Jeffrey D Greenberg
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study., Philip Mease, Désirée van der Heijde, Robert Landewé, Shephard Mpofu, Proton Rahman, Hasan Tahir, Atul Singhal, Elke Boettcher, Sandra Navarra, Karin Meiser, Aimee Readie, Luminita Pricop, and Ken Abrams
The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis., Philippe Mertz, Alexandre Belot, Ricard Cervera, Tyng Yu Chuah, Lorenzo Dagna, Laura Damian, Debashish Danda, David D'cruz, Gerard Espinosa, Camille Frances, David Jayne, Kong Kok Ooi, Eugene J Kucharz, Robert Lebovics, Isabelle Marie, Guillaume Moulis, Stanford Peng, Aman Sharma, Noboru Suzuki, Toshio Tanaka, Ronald Van Vollenhoven, Jean Sibilia, Jacques Eric Gottenberg, François Chasset, and Laurent Arnaud
Correction to: Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison., Peter Nash, Iain B McInnes, Philip Mease, Howard Thom, Matthias Hunger, Andreas Karabis, Kunal Gandhi, Shephard Mpofu, and Steffen M Jugl
Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison., Peter Nash, Iain B McInnes, Philip Mease, Howard Thom, Matthias Hunger, Andreas Karabis, Kunal Gandhi, Shephard Mpofu, and Steffen M Jugl
Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)., Peter Nash, Philip Mease, Iain B McInnes, Proton Rahman, Christopher T Ritchlin, Ricardo Blanco, Eva Dokoupilova, Mats Andersson, Radhika Kajekar, Shephard Mpofu, and Luminita Pricop
PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials., Ana-Maria Orbai, Richard Holland, Ying Ying Leung, William Tillett, Niti Goel, Robin Christensen, Neil McHugh, Laure Gossec, Maarten de Wit, Pil Højgaard, Laura C Coates, Philip Mease, Julie Birt, Lara Fallon, Oliver FitzGerald, Alexis Ogdie, Beverly Shea, Vibeke Strand, Kristina Callis Duffin, Peter Tugwell, Dorcas Beaton, and Dafna D Gladman
The International Consortium for Health Outcome Measurement (ICHOM)Set of Outcomes that Matter to People Living with Inflammatory Arthritis Consensus from an international Working Group., Martijn A H Oude Voshaar, Zofia Das Gupta, Johannes W J Bijlsma, Annelies Boonen, Jeffrey Chau, Delphine S Courvoisier, Jeffrey R Curtis, Benjamin Ellis, Sofia Ernestam, Laure Gossec, Christine Hale, Jennifer Hornjeff, Katy Y Y Leung, Merav Lidar, Phillip Mease, Kaleb Michaud, Girish M Mody, Mwidimi Ndosi, Christina H Opava, Geraldo R C Pinheiro, Matthew Salt, Enrique R Soriano, William J Taylor, Maria J H Voshaar, Angelique E A M Weel, Maarten de Wit, Nico Wulffraat, Mart A F J van de Laar, and Harald E Vonkeman
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force., Josef S Smolen, Monika Schöls, Jürgen Braun, Maxime Dougados, Oliver FitzGerald, Dafna D Gladman, Arthur Kavanaugh, Robert Landewé, Philip Mease, Joachim Sieper, Tanja Stamm, Maarten de Wit, Daniel Aletaha, Xenofon Baraliakos, Neil Betteridge, Filip van den Bosch, Laura C Coates, Paul Emery, Lianne S Gensler, Laure Gossec, Philip Helliwell, Merryn Jongkees, Tore K Kvien, Robert D Inman, Iain B McInnes, Mara Maccarone, Pedro M Machado, Anna Molto, Alexis Ogdie, Denis Poddubnyy, Christopher Ritchlin, Martin Rudwaleit, Adrian Tanew, Bing Thio, Douglas Veale, Kurt de Vlam, and Désirée van der Heijde
Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2., Filip Van den Bosch, Philip Mease, Joachim Sieper, Dominique L Baeten, Yinglin Xia, Su Chen, Aileen L Pangan, and In-Ho Song
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial., Désirée van der Heijde, James Cheng-Chung Wei, Maxime Dougados, Philip Mease, Atul Deodhar, Walter P Maksymowych, Filip Van den Bosch, Joachim Sieper, Tetsuya Tomita, Robert Landewé, Fangyi Zhao, Eswar Krishnan, David H Adams, Beth Pangallo, and Hilde Carlier
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis., Désirée van der Heijde, Atul Deodhar, Oliver FitzGerald, Roy Fleischmann, Dafna Gladman, Alice B Gottlieb, Bengt Hoepken, Lars Bauer, Oscar Irvin-Sellers, Majed Khraishi, Luke Peterson, Anthony Turkiewicz, Jürgen Wollenhaupt, and Philip Mease
Correction: 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis., Désirée van der Heijde, Atul Deodhar, Oliver FitzGerald, Roy Fleischmann, Dafna Gladman, Alice B Gottlieb, Bengt Hoepken, Lars Bauer, Oscar Irvin-Sellers, Majed Khraishi, Luke Peterson, Anthony Turkiewicz, Jürgen Wollenhaupt, and Philip Mease
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)., Désirée van der Heijde, Dafna D Gladman, Mitsumasa Kishimoto, Masato Okada, Suchitrita S Rathmann, Susan R Moriarty, Catherine L Shuler, Hilde Carlier, Olivier Benichou, and Philip J Mease
